An observational study in Circulatory Failure / Shock State and Fluid Therapy, sponsored by University Hospital, Bordeaux. Recruiting at 8 sites in France. Open to participants aged 0 Days to 15 Years. Per ClinicalTrials.gov, last updated 2025-12-01.
Sponsored by University Hospital, Bordeaux · Observational
Among 107 studies in Shock with a site in France — 24 open to participants now, 27 under way, 1 of them phase 3. Shock · France.
Among the 107 studies in Shock with a site in France, this one is the 26th largest by planned enrollment of the 61 observational ones that give a count, is one of 5 that started in 2025, is one of 61 observational ones, reaches primary completion later than 10 of the 26 other live ones, and was the 95th registered.
487 studies on the registry are indexed under Shock; 107 are open to participants now.
Browse Shock studies →24 of the 107 studies in Shock with a site in France are open now. Recruiting first, the newest first:
CHU de Reims · Sites in France
Ages 18+
Centre Hospitalier Universitaire Dijon · Sites in France
Ages 18+
Bicetre Hospital · Sites in France
Ages 18+
University Hospital, Montpellier · Sites in France
Ages 0 days–3 mo
University Hospital, Bordeaux · Sites in France
Ages 0 days–15 yrs
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 68 Shock studies recruiting now, 52 (76%) set no upper age limit and 11 (16%) stop at 75 or younger; 9 take children under 18; 4 take healthy volunteers.
This study: 0 Days to 15 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
107 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 110 is close to the median of 100 across 247 observational studies indexed under Shock.
Median enrollment 139 across the 46 interventional studies, 100 across the 61 observational. Of the 66 that completed or were terminated, 2 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 107 have an industry lead sponsor. The 10 most frequent:
University Hospital, Bordeaux is the lead sponsor of 806 studies on the registry; 197 are open to participants now.
University Hospital, Bordeaux has 6 studies filed under Shock — fewer than ten, so there is no comparison to draw.
11 of the studies in Shock with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07724262Bicetre HospitalEvaluation of the Argos System to Estimate Cardiac Output | 2026-12-31 |
| NCT05655065University Hospital, AngersEffects of Increasing Mean Arterial Pressure on Renal Function in Patients With Shock and With Elevated Central Venous Pressure | 2026-12-31 |
| NCT07255469University Hospital, BordeauxMetabolic Fluid Responsiveness in Children | 2027-03-21 |
| NCT07203833Centre Hospitalier Universitaire, AmiensDiagnostic and Prognostic Evaluation of Vasorin During Septic Shock | 2027-04 |
| NCT06839404Bicetre HospitalPharmacodynamic Analysis of the HaemOdynamic Effects of a Standard Fluid BolUS | 2027-06-30 |
Among the 107 studies in Shock with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators aim to validate markers of metabolic fluid-responsiveness in children with acute circulatory failure following cardiac surgery. This would allow physicians to identify which patient could benefit the most from fluid expansion, thus avoiding useless and potentially dangerous fluid expansions that could lead to fluid overload. To this end, The investigators will evaluate the diagnostic accuracy of the ratio of central venous to arterial carbon dioxide tension (Pv-aCO2) to arteriovenous oxygen content (CavO2), a simple biological marker of anaerobic metabolism, for the diagnosis of metabolic fluid responsiveness defined as a significant increase in oxygen consumption (VO2) after fluid expansion.
Acute circulatory failure, defined as a mismatch between oxygen delivery and consumption, is a frequent but serious condition in children after cardiac surgery. Fluid expansion is the cornerstone of acute circulatory failure treatment, but several studies have highlighted the adverse effects of excessive fluid expansion. Therefore, it is crucial to assess the individual benefit-risk ratio before each fluid expansion. Currently, finding fluid responsiveness tests is a major issue in intensive care. Usually, fluid responsiveness is defined as a significant improvement in stroke volume after fluid expansion. However, this is an intermediate objective, as the ultimate goal of the treatment is to restore an adequate balance between oxygen delivery and consumption. In adults, a significant proportion of hemodynamically successful volume expansions (i.e. resulting in a significant increase in stroke volume) are in fact metabolically ineffective, as they do not result in a significant increase in VO2. Certain biological parameters indicating anaerobiosis, such as the Pv-aCO2/CavO2 ratio, could be predictive of metabolic fluid responsiveness (e.g. a significant increase in VO2) in these patients. This has never been investigated in children.
The main objective of this study will be to evaluate the diagnostic accuracy of the Pv-aCO2/DAVO2 ratio at baseline for the diagnosis of metabolic fluid responsiveness, in children hospitalized in intensive care after cardiac surgery, for whom a fluid expansion was prescribed by the physician in charge.
The investigators will conduct a non-interventional, multicentric diagnostic accuracy study in French pediatric intensive care units. VO2 will be measured at baseline (e.g. before fluid expansion) and within 1h after fluid expansion by the combination of echocardiographic assessment and both arterial and venous blood gas. Blood gas are routinely measured, in patients already implanted with arterial and central line, to help manage acute circulatory failure. Echocardiography assessment, which is noninvasive and nonradiative, is also a common practice in this situation. Additional simple demographic, hemodynamic and clinical data will be collected at baseline and within 1 hour after fluid expansion, if monitored. No supplemental blood test or invasive parameter will be collected. These data will be collected from standard monitoring and/or from the patient's medical record.
The primary outcome is the diagnostic accuracy (measured by the area under the receiver operating characteristics curve) of the index test (Pv-aCO2/DAVO2 ratio at baseline) for the diagnostic of metabolic fluid responsiveness, defined as a 15% increase in VO2 after fluid expansion compared to baseline (gold standard test).
The secondary outcomes are:
Inclusion criteria: Age between 0 days and 15 years old; Patient hospitalized in an intensive care unit after cardiac surgery; Prescription of a 10ml/kg fluid expansion by the physician in charge; Prescription of arterial and venous blood gas before and after the volume expansion to help manage acute circulatory failure; Patient implanted with a functioning arterial line; Patient implanted with a functioning central venous line in the superior vena cava territory Exclusion criteria: Patient less than 37 weeks' corrected gestational age; Hemodynamic instability making the delay necessary for any test dangerous; Supine position contraindicated or deleterious; Impairment of echocardiographic acoustic window or restless patient making ultrasonography impossible; Opposition to participate expressed by the patient or by a parent or legal guardian Number of subjects: One hundred and ten patients are needed. This was calculated with the Obuchowski method, with an alpha risk of 0.05, a statistical power of 80%, a ratio "responder/non-responder" of 3, a predicted area under the receiver operating characteristics curve of 0.85 (based on previous studies) with a confidence interval greater than 0.75 which is a classic threshold for clinical pertinence.
Statistical analysis: Comparisons between metabolic "responders" and "non-responders" (to fluid expansion) will be performed with Student's t-test or Mann-Whitney test for continuous variables; or with the Chi-2 test or Fisher's exact test for categorical variables.
Metabolic fluid responsiveness represents the gold standard test. Patients will be classified as metabolic fluid responders in case of at least 15% increase in VO2 after fluid expansion, compared to baseline.
Diagnostic accuracy of the index tests will be explored. As multiple cut-offs of theses index tests can be defined, the investigators will report a receiver operating characteristic (ROC) curve which graphically represents the combination of sensitivity and specificity for each possible test positivity cut-off. The area under the ROC curve informs in a single numerical value about the overall diagnostic accuracy of the index test. The Youden index will also be calculated. The ROC curves of all index tests will be compared using a DeLong test.
A p value less than 0.05 will be considered statistically significant.
Patient hospitalized in an intensive care unit after cardiac surgery with a prescription of a 10ml/kg fluid expansion by the physician in charge
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Area under the ROC curve (AUROC, %) of baseline Pv-aCO2/DAVO2 ratio to diagnose metabolic fluid
The primary outcome measure of a diagnostic accuracy study is the discriminative ability of an index test (expressed as an area under the ROC curve) to diagnose a condition (defined by a positive gold-standard reference test). In this study: * The index test is the baseline Pv-aCO2/DAVO2 ratio, i.e. the ratio between the veno-arterial carbon dioxide partial pressure gradient (mmHg) and the difference between arterial and venous oxygen content (ml.dl-1). Oxygen content and carbon dioxide partial pressure are measured by arterial and central venous blood gas analysis. * The condition is "metabolic fluid responsiveness" * The gold-standard reference test to diagnose metabolic fluid responsiveness is a VO2 increase of at least 15% between baseline and after volume expansion (i.e. ((VO2 after volume expansion - VO2 at baseline) / VO2 at baseline) \> 15%). VO2 (ml/min/m2) will be measured as follow: VO2=(10.CO.DAVO2)/(Body Surface Area), where CO (ml.min-1) is the cardiac output, measured b
Time frame: at baseline
AUROC (%) of the following index test to diagnose metabolic fluid responsiveness (same definition as above )
Baseline arterial lactate (mmol.L-1), from an arterial blood gas analysis
Time frame: at baseline
AUROC (%) of the following index test to diagnose metabolic fluid responsiveness (same definition as above )
Baseline central venous oxygen saturation (%), from a central venous blood gas analysis
Time frame: at baseline
AUROC (%) of the following index test to diagnose metabolic fluid responsiveness (same definition as above )
Baseline Pv-aCO2 (mmHg), from an arterial and central venous blood gas analysis
Time frame: at baseline
Subgroup analysis of the primary outcome
age, type of fluid expansion, circulatory physiology
Time frame: at baseline
Correlation between metabolic fluid responsiveness and the following
* Age (0 - 2 years / 2 - 5 years / 5 - 15 years) * Sex * Weight * Number of fluid expansion during the last 24 h * Baseline Heart rate * Baseline arterial pressure * Baseline urine output * Baseline capillary refill time * Baseline mottling * Baseline left atrial pressure, if monitored as usual care * Baseline PELODS2 score * Type of volume expansion (albumin or crystalloid) * % of increase in cerebral near-infrared regional spectrophotometry (NIRS, %) ( baseline / after volume expansion) * % of increase in systemic near-infrared regional spectrophotometry (NIRS, %) ( baseline / after volume expansion) * % of increase in mean perfusion pressure (i.e. difference between mean arterial pressure and central venous pressure) ( baseline / after volume expansion) * % of increase in central venous pressure ( baseline / after volume expansion) * Hemodynamic profile
Time frame: at baseline
Correlation between metabolic fluid responsiveness and the following
* Length of mechanical ventilation (days), evaluated 28 days after inclusion * Intensive care unit length of stay (days), evaluated 28 days after inclusion. * Mortality at 28 days after inclusion
Time frame: at baseline , 28 days
Started Mar 2025 (actual). Primary completion is estimated for Mar 2027, 24 months after the start.
Of 120 non-industry observational studies under Shock, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 52. This study's planned 24 months is close to that.
Counting every sponsor, half of 127 studies reached it within 26 months; a quarter within 12 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Bordeaux →